{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:45:32Z","timestamp":1768567532776,"version":"3.49.0"},"posted":{"date-parts":[[2024,9,4]]},"group-title":"Psychiatry and Clinical Psychology","reference-count":26,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Borderline Personality Disorder (BPD) is characterized by rapidly shifting emotional, interpersonal, and behavioral symptoms, and is often co-morbid with mood and anxiety disorders. Females are more likely to be diagnosed with BPD than males and exhibit greater functional impairment. Hormonal fluctuations, particularly in estrogen levels, may influence the manifestation of BPD symptoms. Here we investigated the influence of estrogen-suppressing contraceptives on behavioral and functional difficulties in BPD. The analytical sample included 348 females ages 18-50 undergoing residential treatment for psychiatric disorders, with 131 having a BPD diagnosis. Patients were categorized based on their contraceptive method: 1) Estrogen-suppressing contraceptives (N=145) and 2) Naturally cycling (N=203). Interaction models tested the impact of estrogen-suppressing contraceptives on the relationship between BPD diagnosis and behavioral and functional difficulties at admission and discharge, assessed by the four Behavior and Symptom Identification Scale (BASIS-32) domains: difficulties in relationships, daily living, depression\/anxiety, and impulsivity. Females with a BPD diagnosis were more likely to use estrogen-suppressing contraceptives compared to those without BPD (p=0.04). However, estrogen-suppressing contraceptive use was not associated with behavioral and functional difficulties at admission, discharge, or over time. Estrogen-suppressing contraceptives moderated the association between BPD diagnosis and difficulties in relationships (p=0.004), difficulties in daily living (p=0.01), and depression\/anxiety symptoms (p=0.004). Patients with BPD expressed increased behavioral and functional difficulties at admission, discharge, and over time only if naturally cycling (p&lt;0.003). Our findings suggest that estrogen-suppressing contraceptives may help to regulate the rapidly shifting emotional, interpersonal, and behavioral symptoms in females with BPD by stabilizing estrogen levels.<\/jats:p>","DOI":"10.1101\/2024.09.04.24313069","type":"posted-content","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T22:45:10Z","timestamp":1725489910000},"source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Estrogen-Suppressing Contraceptives on Behavioral and Functional Difficulties in Borderline Personality Disorder"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1575-8642","authenticated-orcid":false,"given":"Seyma","family":"Katrinli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex O.","family":"Rothbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raneeka","family":"DeMoss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Michopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024090613400611000_2024.09.04.24313069v1.1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"11","key":"2024090613400611000_2024.09.04.24313069v1.2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11920-019-1096-y","article-title":"Ovarian Hormones as a Source of Fluctuating Biological Vulnerability in Borderline Personality Disorder","volume":"21","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"2024090613400611000_2024.09.04.24313069v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(99)90123-2"},{"issue":"12","key":"2024090613400611000_2024.09.04.24313069v1.4","doi-asserted-by":"crossref","first-page":"e0279015","DOI":"10.1371\/journal.pone.0279015","article-title":"Sex differences in borderline personality disorder: A scoping review","volume":"17","year":"2022","journal-title":"PLoS One"},{"key":"2024090613400611000_2024.09.04.24313069v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00432-9"},{"issue":"1","key":"2024090613400611000_2024.09.04.24313069v1.6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2215-0366(16)30358-3","article-title":"Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones","volume":"4","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"2024090613400611000_2024.09.04.24313069v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.05.004"},{"key":"2024090613400611000_2024.09.04.24313069v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsycho.2015.03.016"},{"issue":"12","key":"2024090613400611000_2024.09.04.24313069v1.9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1017\/S0033291718001253","article-title":"Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System","volume":"48","year":"2018","journal-title":"Psychol Med"},{"issue":"2","key":"2024090613400611000_2024.09.04.24313069v1.10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ab.21877","article-title":"Differential effects of the menstrual cycle on reactive and proactive aggression in borderline personality disorder","volume":"46","year":"2020","journal-title":"Aggress Behav"},{"key":"2024090613400611000_2024.09.04.24313069v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00068-9"},{"issue":"3","key":"2024090613400611000_2024.09.04.24313069v1.12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.18773\/austprescr.2022.025","article-title":"Hormonal contraception and mood disorders","volume":"45","year":"2022","journal-title":"Aust Prescr"},{"issue":"11","key":"2024090613400611000_2024.09.04.24313069v1.13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamapsychiatry.2016.2387","article-title":"Association of Hormonal Contraception With Depression","volume":"73","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2024090613400611000_2024.09.04.24313069v1.14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12884-024-06587-9","article-title":"Assessing the impact of contraceptive use on mental health among women of reproductive age - a systematic review","volume":"24","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"2024090613400611000_2024.09.04.24313069v1.15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.psyneuen.2016.11.033","article-title":"Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial","volume":"76","year":"2017","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"2024090613400611000_2024.09.04.24313069v1.16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/1471-0528.17028","article-title":"There is no association between combined oral hormonal contraceptives and depression: a Swedish register-based cohort study","volume":"129","year":"2022","journal-title":"BJOG"},{"key":"2024090613400611000_2024.09.04.24313069v1.17","unstructured":"Eisen SV , Culhane MA . Behavior and Symptom Identification Scale (BASIS-32). The use of psychological testing for treatment planning and outcomes assessment, 2nd ed. Mahwah, NJ, US: Lawrence Erlbaum Associates Publishers; 1999. p. 759\u201390."},{"key":"2024090613400611000_2024.09.04.24313069v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.03.004"},{"key":"2024090613400611000_2024.09.04.24313069v1.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000175834.77215.2e"},{"key":"2024090613400611000_2024.09.04.24313069v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.05.008"},{"key":"2024090613400611000_2024.09.04.24313069v1.21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1218"},{"key":"2024090613400611000_2024.09.04.24313069v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2007.05.013"},{"key":"2024090613400611000_2024.09.04.24313069v1.23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpsychores.2017.10.011","article-title":"Oral contraceptives positively affect mood in healthy PMS-free women: A longitudinal study","volume":"103","year":"2017","journal-title":"J Psychosom Res"},{"key":"2024090613400611000_2024.09.04.24313069v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt038"},{"key":"2024090613400611000_2024.09.04.24313069v1.25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.psyneuen.2016.05.026","article-title":"Increased hair testosterone but unaltered hair cortisol in female patients with borderline personality disorder","volume":"71","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"2024090613400611000_2024.09.04.24313069v1.26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.psyneuen.2015.02.002","article-title":"Increased testosterone levels and cortisol awakening responses in patients with borderline personality disorder: gender and trait aggressiveness matter","volume":"55","year":"2015","journal-title":"Psychoneuroendocrinology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.09.04.24313069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:11:09Z","timestamp":1768507869000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.09.04.24313069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1101\/2024.09.04.24313069","relation":{},"subject":[],"published":{"date-parts":[[2024,9,4]]},"subtype":"preprint"}}